iPSC derived CAR-NK Therapy Development Solution

Are you currently facing challenges such as the high cost and logistical complexities of autologous cell therapies, or the limited scalability and persistence of primary NK cell products? Our iPSC-derived CAR-NK therapy development solution helps you accelerate the creation of highly effective, standardized, and scalable allogeneic cellular immunotherapies through advanced iPSC engineering and comprehensive development platforms.

Introduction

The great success of chimeric antigen receptor (CAR)-T cells has prompted scientists to genetically modify human natural killer (NK) cells with CAR to better treat lethal cancer. NK cells can now be routinely produced from human pluripotent stem cells (PSC). These PSCs provide a novel resource that can be used to produce "off-the-shelf" NK cells with a homogeneous and standardized group for CAR-NK therapy.

Induced PSC (iPSC)-derived CAR-NK therapy represents a transformative leap in cellular immunotherapy. By leveraging the unique self-renewal and differentiation capabilities of iPSCs, this solution provides an unlimited, standardized, and genetically engineerable source of NK cells. This addresses critical limitations of traditional CAR-T and primary NK cell therapies, such as manufacturing complexity, donor variability, and limited persistence.

Fig.1 Produce iPSC-derived natural killer cells expressing CAR.¹

iPSC-derived CAR-NK Therapy Development Solution at Creative Biolabs

At Creative Biolabs, we have developed the iPSC technology platform to produce NK cells derived from CAR-expressing stem cells. This technology platform provides an unlimited source of engineered stem cell-derived CAR-NK immune cells. These PSC-derived NK cells have similar phenotypes and functions to primary lymphocytes isolated from peripheral blood, thereby they can be precisely engineered to introduce the improved anti-tumor activity.

• iPSC-NK Cell Gene Editing Platform

We provide multiple strategies to engineer iPSC-derived NK (iPSC-NK) cells for enhanced functional potential, persistence, and homing. Examples of such gene editing strategies include: (i) strategies aimed at introducing specificity through cleavage-resistant CD16 to combine with therapeutic antibodies or CAR; (ii) strategies aimed at improving the persistence of allogeneic iPSC-NK cells by making cells self-sufficient in terms of growth factors; (iii) strategies aimed at co-expressing CXCR3 to enhance the iPSC-NK cell homing to tumor cells. More customized gene editing strategies can be performed according to your requirements.

• CAR Cell Platform for Manufacturing iPSC-NK Cells

As the leading cell therapeutics biotech that provides cell therapy-related services, Creative Biolabs provides one-stop services for CAR-NK therapy development, including but not limited to:

• CAR-NK Vector Design and Construction
• Virus Packaging & CAR Gene Delivery
• CAR-NK In Vitro Assay
• CAR-NK Preclinical In Vivo Assay
• CAR Cell Clinical Trial

Service Process

Key Advantages

• Precision Genetic Engineering: Advanced platform for efficient, precise modifications to create next-gen CAR-NK with enhanced specificity, persistence, and tailored functions.
• Scalable Standardized Manufacturing: Expertise in iPSC tech for homogeneous master cell banks, enabling large-scale, reproducible CAR-NK production - addressing primary cell scalability issues, ensuring consistent supply.
• Dedicated Project Management: Transparent communication, collaborative partnerships; dedicated managers provide updates/consultation to meet project objectives efficiently.

FAQs

Why Choose Us?

Creative Biolabs stands at the forefront of iPSC-derived CAR-NK therapy development, offering unparalleled expertise and a proven track record. Our commitment to innovation, quality, and client success sets us apart, ensuring your project benefits from the most advanced technologies and scientific insights.

Customer Reviews

"The ability to generate homogeneous, large-scale batches of iPSC-derived CAR-NK cells through Creative Biolabs' platform has fundamentally transformed our manufacturing strategy, solving our long-standing issues with primary NK cell expansion. Their solution facilitated a seamless transition from lab-scale to industrial-scale production." - Prof. M***a S.

"Creative Biolabs' expertise in engineering dual-targeting CAR-NK cells has been instrumental in addressing the heterogeneous nature of our target disease. Their solution delivered a product with potent and sustained cytotoxicity against multiple antigens, providing a more comprehensive therapeutic approach than single-target strategies." - Dr. R***el K.

How to Contact Us

Creative Biolabs is dedicated to advancing the field of cellular immunotherapy through innovative iPSC-derived CAR-NK solutions. Our team of experts is ready to collaborate with you to overcome challenges and accelerate your therapeutic development.

Contact our team for more information and to discuss your project.

Reference

1. Lin, Xiaotong et al. "IPSC-derived CAR-NK cells for cancer immunotherapy." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 165 (2023): 115123. https://doi.org/10.1016/j.biopha.2023.115123. Distributed under Open Access License CC BY 4.0, without modification.